Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RGLS

Regulus Therapeutics (RGLS) Stock Price, News & Analysis

Regulus Therapeutics logo

About Regulus Therapeutics Stock (NASDAQ:RGLS)

Advanced Chart

Key Stats

Today's Range
$8.16
$8.16
50-Day Range
$7.87
$8.30
52-Week Range
$0.83
$8.35
Volume
N/A
Average Volume
1.02 million shs
Market Capitalization
$564.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.80
Consensus Rating
Hold

Company Overview

Receive RGLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regulus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RGLS Stock News Headlines

Novartis completes acquisition of Regulus Therapeutics
Man Who Called Nvidia at $1.10 Says Buy This Now...
In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.tc pixel
Regulus Therapeutics Inc.
See More Headlines

RGLS Stock Analysis - Frequently Asked Questions

Regulus Therapeutics Inc. (NASDAQ:RGLS) issued its quarterly earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.14.

Regulus Therapeutics's stock reverse split before market open on Wednesday, June 29th 2022.The 1-10 reverse split was announced on Wednesday, June 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Regulus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Eli Lilly and Company (LLY).

Company Calendar

Last Earnings
5/08/2025
Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RGLS
CIK
1505512
Fax
N/A
Employees
30
Year Founded
2007

Price Target and Rating

High Price Target
$11.00
Low Price Target
$7.00
Potential Upside/Downside
+7.8%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$46.36 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-57.53%
Return on Assets
-53.26%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.31
Quick Ratio
16.31

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.17 per share
Price / Book
6.97

Miscellaneous

Outstanding Shares
69,230,000
Free Float
66,222,000
Market Cap
$564.92 million
Optionable
Optionable
Beta
0.35

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:RGLS) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners